Commercial-Scale Oligonucleotide / ASO CDMOs
Oligonucleotide / ASO manufacturers on CDMO Signal: 7 listed, 7 with a Signal Score. Together they have 20 FDA inspections on file (including 6 NAI, 14 VAI and 0 OAI) and 40 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure solid-phase synthesis scale, backbone chemistry, or conjugation. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-10-15. Methodology. This page is the commercial-scale filter: a high Signal Score or a broad ClinicalTrials.gov footprint. It is not a list of approved commercial products.
Oligonucleotide CDMOs make antisense oligonucleotides (ASOs), siRNAs, and related nucleic-acid drugs by solid-phase synthesis, with downstream purification and conjugation (e.g. GalNAc). The segment has grown sharply alongside approved ASO and siRNA therapeutics.
Choosing an oligonucleotide CDMO turns on synthesis scale, chemistry breadth (phosphorothioate backbones, 2'-modifications, conjugation), purity, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 6 NAI (no action), 14 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Italy (16), United States (14), Spain (10), Belgium (5), Germany (5).
Last updated 2026-10-15. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
AJ
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 2 |
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
|
83.1 | 99.3 | 5 insp · 17 GMP | 2025-11-14 · NAI | — | — |
| 3 |
KE
Seraing, BE
|
81.6 | 99.9 | 1 insp · 4 GMP | 2024-02-26 · VAI | — | — |
| 4 |
ND
Milford, MA
|
80.3 | 100.0 | 4 insp · 0 GMP | 2026-08-12 · NAI | — | — |
| 5 |
BA
|
79.5 | 94.3 | 5 insp · 0 GMP | 2026-05-20 · VAI | — | — |
| 6 |
CRA
|
79.5 | 100.0 | 2 insp · 18 GMP | 2025-12-02 · NAI | — | — |
| 7 |
PP
|
77.4 | 98.4 | 3 insp · 0 GMP | 2025-05-15 · VAI | — | — |